Long-term outcomes in Hurler syndrome
Thanks to haematopoietic stem cell transplantation (HSCT), enzyme replacement therapy (ERT) and better supportive care, many people with Hurler syndrome (severe MPS I, MPS I-H) now live into adolescence and adulthood. Survival is dramatically improved compared with the natural history, and many organ problems are better controlled.
At the same time, most patients still live with significant long-term health issues, particularly affecting movement, hearing, vision, heart, lungs and day-to-day function, so the overall picture is one of better, but still incomplete, outcomes.
Every person is different; this page describes group trends, not individual predictions
Survival, health and quality of life
When doctors talk about “long-term outcomes” they usually mean:
Survival
How long people live
Organ Function
Heart, lungs, brain, bones, eyes, ears
Abilities
Walking, self-care, learning, work, social life
Quality of Life
Pain, fatigue, independence, wellbeing
Hurler syndrome used to be almost uniformly fatal in early childhood. With HSCT and ERT, many patients now survive well into their 20s, 30s and beyond, but almost all continue to require specialist care.
Survival trends in transplanted Hurler patients
Large international cohorts show that, in experienced centres:
- Most children with MPS I-H who survive the first year after HSCT are alive many years later.
- In one 3-decade follow-up of successfully transplanted patients, almost all survivors were still alive at a median age of ~21 years (range around 8–36 years).
Modern series using optimised donor selection and conditioning report engrafted survival rates >80–90 percent in specialist centres.
Key points:
✓HSCT has changed the natural history from very early death to survival into adulthood for many patients.
✓Survival is best when transplant is done early (often <2–2.5 years) and when a good donor and experienced centre are available.
Survival and organ function with long-term laronidase
In attenuated MPS I and in patients who do not have HSCT, ERT is the main disease-specific therapy. Registry and cohort data show that:
- Long-term laronidase treatment leads to disease stabilisation in many patients over an average of about six years of follow-up.
- Earlier treatment (younger age at start) is associated with better preservation of lung function, walking distance, height and slower progression of valve disease and corneal clouding.
- Ten-year survival in attenuated MPS I on long-term laronidase is high; when deaths occur they are most often due to cardiac or pulmonary complications, highlighting persistent risk in these systems.
For severe MPS I-H patients who cannot have HSCT, ERT and intensive supportive care can improve organ function and comfort, but cannot fully match the survival and neurocognitive benefits of early HSCT.
Thinking, learning and everyday abilities
After early HSCT
Transplant performed early in life can preserve or partially preserve neurocognitive function, especially if carried out before marked developmental regression.
Many children attend mainstream or supported schooling; others have more significant learning difficulties and need intensive educational support.
Typical patterns reported:
- Some children achieve near-average cognitive scores, particularly with very early diagnosis and HSCT.
- Others have mild to moderate learning disability but can still communicate, participate in school and enjoy family life.
- A minority have more severe cognitive involvement, often linked to later treatment or more aggressive disease.
Functional skills:
- Over time, many transplanted patients show limitations in gross and fine motor skills, slower walking speed, difficulty with stairs and challenges with tasks needing dexterity (buttons, handwriting).
Overall, HSCT changes neurocognitive outcome from inevitable, rapid decline to a spectrum, ranging from near-typical function to moderate disability.
Spine, hips, joints and mobility over decades
Long-term studies consistently identify bone and joint disease as one of the least fully corrected aspects of Hurler syndrome:
- Even after successful HSCT, most patients have progressive dysostosis multiplex, including kyphosis, scoliosis, hip dysplasia and genu valgum.
- Many require multiple orthopaedic surgeries (spine, hips, legs, carpal tunnel) spread over childhood, adolescence and adulthood.
- Pain, stiffness and reduced mobility are common; some patients become wheelchair dependent or rely on walking aids as they move into adulthood.
- Reviews emphasise that HSCT and ERT can slow progression but rarely normalise skeletal development, because bone and cartilage receive relatively low levels of circulating enzyme.
Heart and lung function in the long term
After HSCT
- HSCT improves survival and can slow progression of valve and myocardial disease, but valvular problems often remain and can still progress, sometimes requiring valve surgery.
- Long-term follow-up shows that cardiopulmonary complications remain an important cause of morbidity and, in some series, mortality.
With long-term ERT (especially attenuated MPS I)
- Laronidase is associated with stabilisation of cardiac and pulmonary function in many attenuated patients, particularly when started early.
Nonetheless, registry data indicate that cardiac and respiratory disease remain leading causes of death in this group.
Important: This means that even in apparently stable patients, regular cardiology and respiratory follow-up is crucial throughout life.
Heart and lung function in the long term
Vision
HSCT has limited impact on existing corneal clouding and does not always prevent progression; some patients ultimately need corneal transplant.
Hearing
Hearing loss (conductive, sensorineural or mixed) remains common despite grommets, hearing aids and ENT surgery, and often worsens with age.
These sensory issues can significantly affect schooling, employment and independence, which is why regular ophthalmology and audiology reviews are a standard part of long-term care plans.
Beyond tests and scans
Beyond tests and scans
Studies and clinical experience highlight that many adolescents and adults with Hurler syndrome:
- Report chronic pain, fatigue and limited stamina
- Experience challenges with body image, anxiety and low mood
- Face barriers to education, employment, relationships and independent living
May develop late-onset mental health problems, including depression and attention difficulties.
Hearing
Despite challenges, many also report:
✓Strong family and peer relationships
✓Engagement in adapted hobbies and sports
✓A sense of purpose through advocacy, education and community involvement
Quality of life is strongly influenced by timely supportive care, mental health support, educational planning and social inclusion, not just by HSCT/ERT status.
Why timing matters
Multiple studies across MPS I show that earlier diagnosis and treatment improve long-term outcomes:
Earlier HSCT (before major neurocognitive decline and severe organ damage) is associated with better cognitive and functional outcomes and fewer complications.
Starting ERT at a younger age in attenuated MPS I helps maintain lung function, walking distance, growth and slower progression of cardiac and eye disease.
This underpins current emphasis on:
→Newborn screening (where available)
→Rapid referral to specialist centres
→Early, decisive discussion about HSCT and/or ERT options
Thinking about the future
Every child and adult with Hurler syndrome is different, but some themes are common:
- HSCT and ERT can change the story from early death to many years of life.
- Most people will still need regular hospital visits, operations and therapies.
- School, friendships, hobbies and family life are still very much possible, although they may need more planning and support.
Helpful questions to discuss with your team:
- What are the main things we should watch for over the next 1–2 years?
- How will you track my child’s learning, mobility, heart and lungs over time?
- What can we do now to protect future options – for example, physiotherapy, hearing and vision checks, mental health support?
How will you help us plan for teenage years and adulthood?
Points to emphasise in clinic
1.HSCT and ERT are disease-modifying, not curative; residual disease and increasing disability are common in long-term survivors.
2.Long-term cohorts show that CNS, bone, heart, eye and lung disease remain major drivers of morbidity and reduced quality of life.
3.Registry and cohort data support early treatment (HSCT or ERT) as a key determinant of better functional and survival outcomes.
4.Lifelong multidisciplinary follow-up is essential, with explicit attention to pain, fatigue, mental health and social participation.
5.Participation in registries and long-term follow-up studies helps refine prognostic information and evaluate emerging therapies.
Key points about long-term outcomes
✓
HSCT and ERT have transformed Hurler syndrome from an early-fatal disease into a condition where many patients survive into adulthood, but most live with significant residual disease.
✓
Long-term problems particularly affect bones and joints, heart, lungs, eyes, hearing and functional abilities, even after early HSCT.
✓
Early diagnosis and early treatment (HSCT and/or ERT) are strongly linked to better survival and functional outcomes.
✓
Quality of life depends not only on HSCT/ERT but also on intensive multidisciplinary and supportive care, mental health support and social inclusion.
✓
Persistent limitations of current treatments create a clear rationale for ongoing research and new therapies, particularly for CNS, skeletal and residual systemic disease.
What to read next
Current treatments overview
Limitations of current treatments
Why residual disease remains and what gaps exist
Supportive and multidisciplinary care
How long-term follow-up and symptom management work